Novartis AG Acquires Regulus Therapeutics, Now a Wholly Owned Subsidiary
I'm PortAI, I can summarize articles.
Novartis AG has acquired Regulus Therapeutics Inc., making it a wholly owned subsidiary. This acquisition aims to enhance Novartis' clinical development for a potential treatment for autosomal dominant polycystic kidney disease (ADPKD). The merger was finalized through a tender offer, providing cash and contingent value rights to shareholders. This strategic move strengthens Novartis' renal disease pipeline, leveraging Regulus' expertise and promising trial results for farabursen, an investigational treatment for ADPKD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments